Black Diamond Therapeutics, Inc. (BDTX) vs Novogen Limited (KZIA)

Black Diamond Therapeutics, Inc. and Novogen Limited are both Biotechnology companies. Black Diamond Therapeutics, Inc. and Novogen Limited are of similar size ($111.8M and $108.6M). Across the 9 metrics below, Black Diamond Therapeutics, Inc. leads on 5 and Novogen Limited on 4.

Valuation

Metric BDTX KZIA Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 1.13 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.04 1.46 0.74
EV/Sales n/m n/m 10.73
Earnings yield (39.68%) (2.27%) (28.84%)
Free cash flow yield (30.26%) 0.00% (23.03%)

Profitability

Metric BDTX KZIA Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (37.21%) 0.00% (57.72%)
Return on assets (29.21%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDTX KZIA Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 130.71% 63.24% —
Revenue growth, 5-year CAGR — 11.56% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDTX KZIA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.28 2.87 4.73
Net debt to EBITDA (10.01) 0.30 0.96

Dividend

Metric BDTX KZIA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BDTX KZIA Biotechnology median
Market cap 108.59m 111.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack